Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35581935/
Heart failure with preserved ejection fraction (HFpEF) is an increasingly widespread medical condition, with excessive morbidity and mortality. Recently, for the first time in HFpEF, a reduction in the primary...
Relevance: Herein, we review different approaches to HFpEF phenotyping and present some distinct HFpEF subtypes.
Share
Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35585884/
Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development of heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has been shown to prevent cardiovascular events...
Relevance: Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development of heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has been shown to prevent cardiovascular events and reduce the incidence of heart failure in randomized clinical trials. However, the mechanism of how EMPA...
Share
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35585590/
The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients...
Conclusion: The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data.
Share
Metabolomics study reveals the alteration of fatty acid oxidation in the hearts of diabetic mice by empagliflozin
Source : https://pubs.rsc.org/en/content/articlelanding/2022/MO/D2MO00036A
Empagliflozin (Empa, SGLT2 inhibitor) is widely used in clinical situations for the management of diabetes. It has beneficial effects in reducing cardiac dysfunction and heart failure. However, rare studies have...
Conclusion: These results suggest that fatty acid oxidation is one of the targets for Empa treatment in the heart of db/db mice. This study provided new possibilities for the development of therapeutic interventions for diabetic cardiomyopathy.
Share
Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35506446/
doi: 10.1002/jimd.12509. Online ahead of print. 1 Biologie Hématologique, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. 2 Service de Gastro-Entérologie et Hépatologie Pédiatrique, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. 3 Groupe...
Conclusion: Our data shows that SGLT2 inhibitors are an excellent alternative to treat the neutropenia present in G6PC3-deficiency
Share